bicalutamide has been researched along with goserelin in 120 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (15.00) | 18.2507 |
| 2000's | 54 (45.00) | 29.6817 |
| 2010's | 45 (37.50) | 24.3611 |
| 2020's | 3 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Matzkin, H; Soloway, MS | 1 |
| Kennealey, GT; Vogelzang, NJ | 1 |
| Block, NL; Chodak, G; Kasimis, B; Kennealey, GT; Macramalla, E; Sharifi, R | 1 |
| Crawford, ED | 1 |
| Block, N; Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, M; Venner, P; Vogelzang, N | 2 |
| Chatelain, C; Cosaert, J; Rousseau, V | 1 |
| Iversen, P | 1 |
| Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, MS; Venner, P; Vogelzang, N | 1 |
| Block, NL; Chen, Y; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Block, NL; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellenger, JJ; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Anderson, JB; Baert, L; Blackledge, GR; Carroll, K; Chamberlain, M; Gotting-Smith, K; Iversen, P; Kaisary, AV; Tammela, T; Tyrrell, CJ | 1 |
| Usami, M | 1 |
| Block, NL; Chodak, GW; Klein, EA; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellenger, JJ; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Chatelain, C; Fourcade, RO | 1 |
| Bono, AV; Diamanti, L; Galetti-Prayer, T; Montironi, R; Pagano, F; Santinelli, A; Selvaggi, FP; Zattoni, F | 1 |
| Block, NL; Kelley, RP; Kolvenbag, GJ; McLeod, DG; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ | 1 |
| Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Conti, G; Cruciani, G; Dammino, S; Delliponti, U; Ditonno, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rubagotti, A; Spano, G | 1 |
| Carroll, K; Johnson, R; Kolvenbag, GJ; Sarosdy, MF; Schellhammer, PF | 1 |
| Erman, M; Ruacan, S; Tekuzman, G; Yalçin, S | 1 |
| Biagini, G; Lucarini, G; Mazzucchelli, R; Montironi, R; Pugnaloni, A; Santinelli, A | 1 |
| El-Gabry, EA; Gomella, LG; Strup, SE | 1 |
| Leibowitz, RL; Tucker, SJ | 1 |
| Collette, L; Denis, LJ; Schröder, FH; Studer, UE; Sylvester, RJ | 1 |
| Inoue, K; Kaneko, Y; Maegawa, M; Maekawa, S; Nishimura, K; Ohmori, K; Ushida, H | 1 |
| Amin, P; Chen, T; Dawson, N; Engstrom, C; Hussain, A; Naslund, M | 1 |
| Altwein, JE; Schmidt, A | 1 |
| Bono, A; Comeri, G; Cosciani-Cunico, S; Fiaccavento, G; Guazzieri, S; Lembo, A; Manganelli, A; Mazzucchelli, R; Montironi, R; Muto, G; Pagano, F; Potenzoni, D; Santinelli, A; Selli, C; Selvaggi, FP; Zattoni, F | 1 |
| Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Cortellini, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rigatti, P; Rubagotti, A; Usai, E | 1 |
| Mizokami, A; Namiki, M | 1 |
| Duncan, WE; Harding, P; Howard, RS; McLeod, DG; Preston, DM; Torréns, JI | 1 |
| Abdalla, I; Basu, A; Connell, PP; Jani, AB; Krauz, L; Vijayakumar, S | 1 |
| Henderson, A; Laing, RW; Langley, SE | 1 |
| Albrecht, W; Collette, L; De Reijke, TM; Fava, C; Kariakine, OB; Kil, PJ; Rea, LA; Studer, UE; Whelan, P | 1 |
| Budde, A; Caprano, J; Helpap, B; Hopfenmüller, W; Köllermann, J; Weidenfeld, H; Weidenfeld, M | 1 |
| Huang, W; Iczkowski, KA; Mazzucchelli, R; Montironi, R; Pantazis, CG; Stevens, GR | 1 |
| Akaza, H; Arai, Y; Igawa, M; Kanetake, H; Kumon, H; Matsuda, T; Naito, S; Ohashi, Y; Soeda, A; Usami, M; Yamaguchi, A | 1 |
| Kijima, T; Okuno, T; Sakai, Y; Wakui, M | 1 |
| Aslan, P; Bryant, C; Bucci, J; Diamond, TH; Kersley, JH; Lynch, WB | 1 |
| Gandhok, N; Sartor, O | 1 |
| Ishizuka, N; Kakehi, Y; Kawamoto, H; Naito, S; Nihei, K; Tobisu, K; Yokomizo, A | 1 |
| Benney, M; Gillatt, DA; Okeke, AA; Sugiono, M; Winkler, MH | 1 |
| Al-Qaisieh, B; Ash, D; Bottomley, D; Carey, B; Joseph, J | 1 |
| Akakura, K; Akaza, H; Fukagai, T; Gillatt, D; Keane, T; Klotz, L; Morris, C; Payne, H | 1 |
| Gratzle, J; Jani, AB; Myers, M | 1 |
| Gratzle, J; Jani, AB | 1 |
| Daskivich, TJ; Oh, WK | 1 |
| Augustin, H; Bayer, L; Freibauer, C; Kuber, W; Lunglmayr, G; Pummer, K; Tschurlovich, F | 1 |
| Cecchini, MG; Klima, I; Peternac, D; Studer, UE; Thalmann, GN | 1 |
| Fujisawa, M; Hara, I; Inoue, TA; Miyake, H; Sakai, I | 1 |
| Akdogan, B; Akyol, F; Karabulut, E; Onal, C; Ozen, H; Ozyigit, G; Selek, U | 1 |
| Baba, S; Egawa, S; Fujita, T; Irie, A; Iwamura, M; Kadowaki, K; Kawakami, T; Koh, H; Matsuda, D; Matsumoto, K; Muramoto, M; Okayasu, I; Satoh, T; Shoji, K; Suyama, K; Tabata, K; Yanagisawa, N | 1 |
| Akaza, H; Arai, Y; Hirano, Y; Kagawa, S; Kanetake, H; Naito, S; Ohashi, Y; Sumiyoshi, Y; Takimoto, Y; Terai, A; Usami, M; Yoshida, H | 1 |
| Hasegawa, Y; Masue, N | 1 |
| Arima, K; Onishi, T; Soga, N; Sugimura, Y | 1 |
| Arichi, N; Ichikawa, Y; Kishikawa, H; Nishimura, K; Tokugawa, S; Yoshioka, I | 1 |
| Agarwal, S; Bulpitt, CJ; Dockery, F; Hooper, J; Kemp, M; Nihoyannopoulos, P; Rajkumar, C; Vernon, C | 1 |
| Nemoto, K; Tomita, Y | 1 |
| Brehmer, B; Jakse, G; Makris, A; Wellmann, A | 1 |
| Aghajanian, C; Derosa, F; Esch, J; Hensley, M; Iasonos, A; Juretzka, M; Konner, J; Levine, D; Lewin, S; Park, K; Sabbatini, P; Spriggs, D | 1 |
| Akaza, H; Hinotsu, S; Hirao, Y; Kagawa, S; Kitamura, T; Murai, M; Naito, S; Namiki, M; Ogawa, O; Tsukamoto, T; Usami, M; Yamanaka, H | 1 |
| Bradley, DA; Chenevert, TL; Galban, CJ; Hussain, M; Jacobson, JA; Johnson, TD; Lee, KC; Meyer, CR; Pienta, KJ; Rehemtulla, A; Ross, BD | 1 |
| Crawford, ED; Flaig, TW; Glodé, LM; Hussain, MH; Raghavan, D; Stadler, WM; Tangen, CM | 1 |
| Arima, K; Soga, N; Sugimura, Y | 1 |
| Kempkensteffen, C; Kleinschmidt, K; Köllermann, J; Pantel, K; Rau, T; Schostak, M; Weikert, S | 1 |
| Adam, TJ; Chen, SC; Curtis, KK; Gornet, MK; Pruthi, RK | 1 |
| Barret, E; Cathala, N; Cathelineau, X; Mombet, A; Prapotnich, D; Rozet, F; Sanchez-Salas, RE; Vallancien, G | 1 |
| Burri, RJ; Cesaretti, JA; Ho, AY; Stock, RG; Stone, NN | 1 |
| Akdas, AM; Burch, PA; Crawford, ED; Dipaola, RS; Donnelly, BJ; Goldman, B; Higano, CS; Hussain, M; Petrylak, DP; Small, EJ; Sundram, SK; Tangen, C; Wilding, G | 1 |
| Battaglia, M; Bettocchi, C; Ditonno, P; Fuzio, P; Lucarelli, G; Perlino, E; Selvaggi, FP | 1 |
| Arslan, G; Efe, E; Onal, C; Topkan, E; Yavuz, A; Yavuz, M | 1 |
| Matousek, RH; Sherwin, BB | 1 |
| Coleman, CN; Gulley, J; Kamrava, M; Kaushal, A; Madan, RA; Tsang, KY | 1 |
| Alonzi, R; Collins, DJ; D'Arcy, JA; Hoskin, PJ; Padhani, AR; Saunders, MI; Stirling, JJ; Taylor, NJ | 1 |
| Chan, MM; Cheng, CW; Kanesvaran, R; Khoo, D; Phipps, C; Tan, MH | 1 |
| Lin, CP; Peng, T; Xu, XM; Zhuang, HY | 1 |
| Leer, JW; Schimmel, EC; Stalmeier, PF; van Lin, EN; van Tol-Geerdink, JJ | 1 |
| Crawford, ED; Dawson, NA; Dorff, TB; Flaig, TW; Glode, LM; Haas, NB; Hussain, MH; Sakr, WA; Swanson, GP; Tangen, CM; Thompson, IM; Vogelzang, NJ; Wood, DP | 1 |
| Kobayashi, M; Kurokawa, S; Morita, T; Nukui, A; Suzuki, K | 1 |
| Barrett, T; Gill, AB; Gnanapragasam, VJ; Graves, MJ; Griffiths, JR; Joubert, I; Kataoka, MY; Lomas, DJ; McLean, MA; Neal, D; Priest, AN; Sala, E; Stearn, S | 1 |
| Badiozamani, K; Douglass, E; Hsi, A; Madsen, B; Pham, HT; Song, G; Vuky, J; Warren, S | 1 |
| Both, S; Guzzo, TJ; Haas, NB; Hwang, WT; Jang, JW; Vapiwala, N; Wein, AJ | 1 |
| Erkkilä, T; Isola, J; Kaipia, A; Kujala, P; Lähdesmäki, H; Larjo, A; Lehmusvaara, S; Seppälä, J; Tammela, TLj; Tuominen, VJ; Urbanucci, A; Visakorpi, T; Waltering, K | 1 |
| Hayashi, N; Hori, Y; Ogura, Y; Soga, N; Sugimura, Y | 1 |
| Aaltomaa, S; Axcrona, K; Colli, E; da Silva, CM; Damber, JE; Klarskov, P; Ozen, H; Tankó, LB | 1 |
| Erkkilä, T; Jalava, S; Kaipia, A; Kujala, P; Lähdesmäki, H; Lehmusvaara, S; Seppälä, J; Tammela, TL; Urbanucci, A; Visakorpi, T | 1 |
| Bednarski, SR; Chao, HH; Concato, J; Hu, S; Li, CS; Luo, X; Rose, M; Uchio, E; Zhang, S | 1 |
| Date, S; Hirayama, K; Mukaisho, K; Nagashima, T; Niiro, M; Okihara, K | 1 |
| Riedl, CR; Stangelberger, A; Susani, M | 1 |
| Bergqvist, PB; Guerif, S; Khoo, V; Maldonado Pijoan, X; Mason, M; Steidle, C; van der Meulen, E; Wiegel, T | 1 |
| Al-Ali, G; Anderson, J; Colli, E; Gomez Veiga, F; Gual, JB; Persson, BE; van der Meulen, E; Wirth, M | 1 |
| Bubley, G; Buckle, G; Ernstoff, MS; Kantoff, PW; Morganstern, DE; Nakabayashi, M; Taplin, ME; Walsh, W; Xie, W | 1 |
| Cohen, P; Corman, JM; Dalkin, BL; Dean, JP; Ellis, WJ; Haugk, K; Lin, DW; Montgomery, B; Mostaghel, E; Nelson, PS; Plymate, SR; Sprenger, CC; Wan, J | 1 |
| Corn, PG; DePetrillo, TA; Heath, E; Kuban, D; Maier, J; Mathew, P; Meyn, R; Song, DY | 1 |
| Berry, DL; Crawford, ED; Dawson, NA; Donnelly, BJ; Ely, B; Higano, CS; Hussain, M; Kanaga Sundaram, S; Liu, G; Moinpour, CM; Prescott, S; Quinn, DI; Raghavan, D; Schellhammer, PF; Small, EJ; Tangen, CM; Thompson, IM; Vaishampayan, UN; Venner, PM; Vogelzang, NJ; Wilding, G | 1 |
| Aarnes, EK; Flatmark, K; Holm, R; Lilleby, W; Lyng, H; Nesland, JM; Ragnum, HB; Ree, AH; Røe, K; Seierstad, T; Vlatkovic, L | 1 |
| Cheng, HH; Fu, ZC; Li, DS; Lin, GS; Luo, HC | 1 |
| Balk, S; Ellis, W; Gulati, R; Hunter Merrill, R; Kantoff, P; Lange, P; Lin, DW; Marck, B; Matsumoto, AM; Montgomery, B; Mostaghel, EA; Nelson, PS; Penning, T; Tamae, D; Taplin, ME; True, LD; Vessella, R | 1 |
| Cui, Y; Li, N; Yan, H; Zhang, Y; Zong, H | 1 |
| Daverede, L; Harnden, P; Jagdev, SP; Paul, A; Ralph, C; Trainor, S; Trigonis, I; Vasudev, NS; Weston, M | 1 |
| Cheng, HH; Cheng, LP; Fu, ZC; Li, DS; Liao, SG; Lin, GS; Luo, HC; Xu, JF; Yin, Q; Yu, QY; Zheng, WF; Zhu, JF | 1 |
| Antes, G; Dahm, P; Grobe, HR; Kunath, F; Meerpohl, JJ; Motschall, E; Rücker, G; Wullich, B | 1 |
| Esa, A; Hara, I; Iki, M; Imanishi, M; Kajikawa, H; Komura, T; Matsuyama, H; Nagao, K; Nishioka, T; Nozawa, M; Ogawa, T; Uejima, S; Uekado, Y; Uemura, H | 1 |
| Amin, MB; Balogh, AG; Bauman, GS; Chinn, DM; Dignam, JJ; Duclos, M; Gomella, LG; Gore, EM; Hunt, D; Lukka, HR; Pisansky, TM; Rosenthal, SA; Rotman, MZ; Sandler, HM; Seider, MJ; Shipley, WU | 1 |
| Aydoğdu, Ï; Çakır, O; Kumral, TL; Ötünçtemur, A; Salturk, Z; Uyar, Y; Yıldırım, G | 1 |
| Ding, Q; Gong, J; Gu, B; Guo, J; Jiang, H; Ma, J; Qiu, W; Sheng, L; Sun, F; Xu, H; Xue, W; Yao, X; Zhu, W | 1 |
| Arai, Y; Hirai, M; Kobayashi, Y; Miyagawa, T; Saito, K; Washino, S | 1 |
| Bosnyak, Z; Malmberg, A; Mason, M; Neijber, A; Richaud, P | 1 |
| Cruz-Conde de Boom, R; de Lara-Simón, IM; Flores-Terry, MÁ; García-Arpa, M | 1 |
| Cassidy-Bushrow, AE; Haque, R; Keating, NL; Potosky, AL; Tsai, HT; UlcickasYood, M; Van Den Eeden, SK; Xu, X | 1 |
| Bertolín-Colilla, M; Deza, G; Lobato-Berezo, A; March-Rodríguez, A; Pujol, RM | 1 |
| García-Perdomo, HA; Reis, LO; Zani, EL | 1 |
| Crawford, ED; Dawson, NA; Dorff, TB; Flaig, TW; Glode, LM; Haas, NB; Hussain, M; Lin, DW; Quinn, DI; Sakr, W; Swanson, GP; Tangen, CM; Thompson, IM; Vogelzang, NJ; Wood, DP | 1 |
| Lei, BH; Lu, ZJ; Wang, Y; Zhang, Y; Zhu, QY; Zou, Q | 1 |
| Bryant, AK; Deka, R; McKay, R; Murphy, JD; Nalawade, V; Rose, BS; Sarkar, RR; Simpson, DR | 1 |
| Barbosa, FG; Buchpiguel, CA; Costa, LB; Dzik, C; Marin, JFG; Nunes, RF; Queiroz, MA | 1 |
| Erdemir, F; Firat, F; Günaydın, B; Markoç, F; Parlaktas, BS; Yaşar, A | 1 |
| Fujita, K; Imamura, R; Kawashima, A; Kiuchi, H; Koh, Y; Miyagawa, Y; Nagahara, A; Nonomura, N; Uemura, M; Ujike, T | 1 |
| Chen, C; Li, J; Shen, P; Wu, B; Wu, F; Xu, T; Yin, X; Yu, L | 1 |
9 review(s) available for bicalutamide and goserelin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent developments in endocrine treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Buserelin; Clinical Trials as Topic; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 1992 |
[Endocrine therapy for prostate cancer in the future].
Topics: Adult; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Survival Rate; Testosterone; Tosyl Compounds | 1998 |
Androgen deprivation for prostatic carcinoma: a rationale for choosing components.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1998 |
[Total androgen blockade].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Castration; Chlormadinone Acetate; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 2002 |
[Reevaluation of MAB therapy and progress of endocrine therapy].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Goserelin; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 2005 |
Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chi-Square Distribution; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Nitriles; Odds Ratio; Oligopeptides; Prostatic Neoplasms; Quality of Life; Time Factors; Tosyl Compounds; Treatment Outcome; Tumor Burden | 2014 |
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Medication Adherence; Nitriles; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds; Triptorelin Pamoate | 2014 |
Estrogen therapy in patients with prostate cancer: a contemporary systematic review.
Topics: Anilides; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Estrogens, Non-Steroidal; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 2018 |
51 trial(s) available for bicalutamide and goserelin
| Article | Year |
|---|---|
Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Follow-Up Studies; Goserelin; Humans; Logistic Models; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Quality of Life; Remission Induction; Survival Rate; Tosyl Compounds; Treatment Failure; United States | 1995 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Survival Rate; Tosyl Compounds; Treatment Failure | 1995 |
French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Goserelin; Humans; Imidazoles; Imidazolidines; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 1994 |
Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Goserelin; Humans; Male; Nitriles; Orchiectomy; Prostatic Neoplasms; Tosyl Compounds | 1994 |
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Drug Synergism; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Nitriles; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Tosyl Compounds | 1996 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Double-Blind Method; Flutamide; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1996 |
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 1997 |
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Castration; Disease Progression; Double-Blind Method; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Quality of Life; Survival Rate; Time Factors; Tosyl Compounds | 1998 |
Comparison of goserelin and leuprolide in combined androgen blockade therapy.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 1998 |
Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Time Factors; Tosyl Compounds; Treatment Outcome | 1999 |
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Black People; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Double-Blind Method; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; White People | 1999 |
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Consumer Product Safety; Disease Progression; Disease-Free Survival; Erectile Dysfunction; Flutamide; Goserelin; Humans; Italy; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prostatic Neoplasms; Quality of Life; Survival Rate; Tosyl Compounds | 1999 |
Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds | 2000 |
Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2001 |
Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Finasteride; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Paclitaxel; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Tosyl Compounds | 2001 |
Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Chemotherapy, Adjuvant; Drug Administration Schedule; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 2002 |
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Flutamide; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2002 |
Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study.
Topics: Analysis of Variance; Anilides; Goserelin; Humans; Male; Middle Aged; Nitriles; Premedication; Prospective Studies; Prostate; Prostatic Neoplasms; Rectum; Tosyl Compounds; Ultrasonography | 2003 |
Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Ja
Topics: Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Double-Blind Method; Goserelin; Humans; Japan; Leuprolide; Lymphatic Metastasis; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Tosyl Compounds; Treatment Outcome | 2004 |
Randomized controlled trial to evaluate radiotherapy +/- endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401.
Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Endpoint Determination; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Radiotherapy Dosage; Survival Rate; Tosyl Compounds | 2005 |
Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cyproterone Acetate; Goserelin; Humans; Injections, Subcutaneous; Male; Nitriles; Pain; Prostatic Neoplasms; Tosyl Compounds | 2005 |
Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma; Cell Proliferation; Gene Expression Regulation, Neoplastic; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Prognosis; Prostatic Neoplasms; Testosterone; Tosyl Compounds; Withholding Treatment | 2006 |
[8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Chemotherapy, Adjuvant; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk; Time Factors; Tosyl Compounds; Treatment Failure | 2006 |
Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.
Topics: Aged; Anilides; Double-Blind Method; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2007 |
Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Estradiol; Goserelin; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Nitriles; Peptide Fragments; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2008 |
A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission.
Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Goserelin; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Tosyl Compounds | 2007 |
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fatal Outcome; Goserelin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Nitriles; Prednisone; Prostatectomy; Prostatic Neoplasms; Risk Assessment; Risk Factors; Southwestern United States; Survival Analysis; Tosyl Compounds | 2008 |
Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Monitoring; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kaplan-Meier Estimate; Leuprolide; Male; Middle Aged; Multivariate Analysis; Nitriles; Patient Selection; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Tosyl Compounds; Treatment Failure | 2008 |
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Estramustine; Goserelin; Humans; Male; Middle Aged; Mitoxantrone; Nitriles; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2009 |
The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Schedule; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Prostatic Neoplasms; Radiation Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Rectum; Tomography, X-Ray Computed; Tosyl Compounds; Treatment Outcome; Urinary Bladder | 2009 |
A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cognition; Drug Administration Schedule; Estradiol; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Neuropsychological Tests; Nitriles; Placebos; Prostatic Neoplasms; Tosyl Compounds | 2010 |
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Goserelin; Humans; Male; Middle Aged; Mitoxantrone; Nitriles; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 2011 |
Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Administration Schedule; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Risk; Tosyl Compounds | 2012 |
Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
Topics: Administration, Oral; Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Bayes Theorem; Castration; Chemotherapy, Adjuvant; Chi-Square Distribution; Finland; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Goserelin; Humans; Injections, Subcutaneous; Male; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Oligonucleotide Array Sequence Analysis; Oncogene Proteins, Fusion; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2012 |
Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Gonadotropin-Releasing Hormone; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Nitriles; Oligopeptides; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome; Tumor Burden | 2012 |
Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate.
Topics: Adenocarcinoma; Anilides; Antineoplastic Agents; Computer Simulation; Gene Expression Regulation, Neoplastic; Gene Fusion; Goserelin; Humans; In Situ Hybridization, Fluorescence; Male; MicroRNAs; Neoadjuvant Therapy; Nitriles; Oligonucleotide Array Sequence Analysis; Oncogene Proteins, Fusion; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds; Tumor Cells, Cultured | 2013 |
Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goser
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Goserelin; Humans; Kallikreins; Male; Neoadjuvant Therapy; Nitriles; Oligopeptides; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Risk Factors; Testosterone; Tosyl Compounds | 2013 |
Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Androgen Antagonists; Anilides; Drug Therapy, Combination; Early Termination of Clinical Trials; Europe; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Nitriles; Oligopeptides; Patient Selection; Prostatic Neoplasms; Sample Size; Time Factors; Tosyl Compounds; Treatment Outcome | 2013 |
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Therapy, Combination; Estramustine; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Retrospective Studies; Taxoids; Time Factors; Tosyl Compounds; Treatment Outcome | 2013 |
Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cohort Studies; Goserelin; Humans; Insulin; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 1; Male; Neoadjuvant Therapy; Nitriles; Obesity; Prostatectomy; Prostatic Neoplasms; Receptor, IGF Type 1; Risk; Secondary Prevention; Somatomedins; Tosyl Compounds; United States | 2013 |
Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Drug Interactions; Feasibility Studies; Goserelin; Humans; Indoles; Leuprolide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Radiotherapy, Intensity-Modulated; Seminal Vesicles; Sunitinib; Tosyl Compounds | 2013 |
Intermittent versus continuous androgen deprivation in prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Confidence Intervals; Drug Administration Schedule; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Penile Erection; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Tosyl Compounds | 2013 |
Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Androgen Antagonists; Androgen Receptor Antagonists; Androsterone; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Azasteroids; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dihydrotestosterone; Dutasteride; Goserelin; Humans; Ketoconazole; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Pilot Projects; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Testosterone; Tosyl Compounds; Treatment Outcome | 2014 |
Long-term quality of life outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with androgen deprivation.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Quality of Life; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Tosyl Compounds; Treatment Outcome; Urinary Incontinence | 2014 |
Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Follow-Up Studies; Goserelin; Humans; Imidazoles; Japan; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Time Factors; Tosyl Compounds; Zoledronic Acid | 2015 |
Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Time Factors; Tosyl Compounds; Treatment Outcome | 2015 |
An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Goserelin; Humans; Hypoglycemic Agents; Male; Metformin; Nitriles; Orchiectomy; Pilot Projects; Prostatic Neoplasms; Tosyl Compounds | 2017 |
Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Nitriles; Oligopeptides; Organ Size; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds; Treatment Outcome | 2017 |
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Biopsy; Combined Modality Therapy; Glucocorticoids; Goserelin; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Nitriles; Prednisone; Prostatectomy; Prostatic Neoplasms; Survival Rate; Tosyl Compounds; Treatment Outcome | 2018 |
[Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer].
Topics: Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Goserelin; Humans; Male; Nitriles; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tosyl Compounds; Treatment Outcome | 2017 |
60 other study(ies) available for bicalutamide and goserelin
| Article | Year |
|---|---|
Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma.
Topics: Androgen Antagonists; Anilides; Antigens, Neoplasm; Biomarkers, Tumor; Buserelin; Goserelin; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 1992 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Controlled Clinical Trials as Topic; Flutamide; Goserelin; Humans; Leuprolide; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 1995 |
Syndrome of inappropriate antidiuretic hormone secretion (SIADH) associated with prostatic carcinoma.
Topics: Abdominal Pain; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Diagnosis, Differential; Fatal Outcome; Goserelin; Humans; Inappropriate ADH Syndrome; Male; Middle Aged; Nitriles; Paraneoplastic Syndromes; Prostatic Neoplasms; Tosyl Compounds; Weight Loss | 2000 |
Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Capillaries; Endothelial Growth Factors; Goserelin; Humans; Immunohistochemistry; Lymphokines; Male; Middle Aged; Neovascularization, Pathologic; Nitriles; Prostatectomy; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Tosyl Compounds; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Goserelin; Humans; Male; Nitriles; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Substance Withdrawal Syndrome; Tosyl Compounds | 2000 |
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
Topics: Androgen Antagonists; Anilides; Clinical Trials, Phase III as Topic; Cyproterone Acetate; Factor Analysis, Statistical; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Meta-Analysis as Topic; Nitriles; Orchiectomy; Prognosis; Prostatic Neoplasms; Research Design; Survival Analysis; Tosyl Compounds; Treatment Outcome | 2001 |
[Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Pilot Projects; Prostatic Neoplasms; Tosyl Compounds | 2001 |
Prostate-specific antigen dynamics predict risk of progression in advanced prostate cancer treated with bicalutamide plus castration.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Goserelin; Humans; Male; Middle Aged; Nitriles; Orchiectomy; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Time Factors; Tosyl Compounds | 2002 |
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Topics: Absorptiometry, Photon; Adenocarcinoma; Aged; Amino Acids; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Biomarkers; Bone Density; Bone Remodeling; Calcium; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Osteoporosis; Prospective Studies; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2002 |
Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Neoadjuvant Therapy; Nitriles; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds | 2003 |
Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Feasibility Studies; Goserelin; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2003 |
Prognosis of stage pT0 after prolonged neoadjuvant endocrine therapy of prostate cancer: a matched-pair analysis.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Matched-Pair Analysis; Neoplasm Staging; Nitriles; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors; Tosyl Compounds | 2004 |
Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Carcinoma; Catalytic Domain; Goserelin; Humans; Immunohistochemistry; Male; Middle Aged; Nitriles; Peptide Fragments; Prostatectomy; Prostatic Neoplasms; Telomerase; Tosyl Compounds | 2004 |
[A case of seminal vesicle cyst due to the obstruction of the ejaculatory duct: possible association with prostate cancer].
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cysts; Diagnostic Imaging; Ejaculatory Ducts; Genital Diseases, Male; Goserelin; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Seminal Vesicles; Tosyl Compounds | 2004 |
Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.
Topics: Aged; Alcohol Drinking; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Comorbidity; Flutamide; Goserelin; Humans; Male; Multivariate Analysis; Nitriles; Osteoporosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Spinal Fractures; Time Factors; Tosyl Compounds; Vitamin D | 2004 |
Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen.
Topics: Adenocarcinoma; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Goserelin; Humans; Immunocompromised Host; Male; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasms, Second Primary; Neutropenia; Nitriles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostate-Specific Antigen; Prostatic Neoplasms; Recurrence; Sepsis; Tosyl Compounds; Vincristine | 2004 |
The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer.
Topics: Adult; Aged; Anilides; Brachytherapy; Goserelin; Humans; Iodine Radioisotopes; Male; Middle Aged; Nitriles; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Tosyl Compounds | 2005 |
Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer.
Topics: Aged; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Brachytherapy; Cohort Studies; Flutamide; Gastrointestinal Tract; Goserelin; Hormones; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prognosis; Prostatic Neoplasms; Radiation Injuries; Radiotherapy; Radiotherapy Dosage; Regression Analysis; Testosterone; Time Factors; Tosyl Compounds; Treatment Outcome; Urogenital System | 2005 |
Late radiotherapy toxicity after prostate cancer treatment: influence of hormonal therapy.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Gastrointestinal Diseases; Goserelin; Humans; Leuprolide; Male; Male Urogenital Diseases; Nitriles; Prostatic Neoplasms; Radiation Injuries; Time Factors; Tosyl Compounds | 2005 |
Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
Topics: Abscess; Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Bone Neoplasms; Delayed-Action Preparations; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds; Treatment Failure | 2006 |
Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyproterone Acetate; DNA, Complementary; Goserelin; Humans; Male; Nitriles; Polymerase Chain Reaction; Prostate-Specific Antigen; Prostatic Neoplasms; RNA, Messenger; Tosyl Compounds | 2006 |
The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Japan; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Preoperative Care; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Time Factors; Tosyl Compounds | 2006 |
Preliminary results of bicalutamide monotherapy on biochemical failure of localized prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Tosyl Compounds; Triptorelin Pamoate | 2006 |
[Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Drug Administration Schedule; Drug Therapy, Combination; Goserelin; Humans; Magnetic Resonance Imaging; Male; Naphthalenes; Nitriles; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2007 |
Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Drug Therapy, Combination; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2007 |
Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy, Needle; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endosonography; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Magnetic Resonance Imaging; Male; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tomography, X-Ray Computed; Tosyl Compounds; Treatment Outcome | 2007 |
Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Cell Differentiation; Goserelin; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2007 |
[Solitary peritoneal carcinomatosis in prostate cancer].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Follow-Up Studies; Goserelin; Humans; Lymph Node Excision; Male; Nitriles; Peritoneal Neoplasms; Peritoneum; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Tosyl Compounds; Transurethral Resection of Prostate; Treatment Outcome | 2007 |
Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Disease-Free Survival; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Nitriles; Orchiectomy; Prognosis; Prostatic Neoplasms; Tosyl Compounds | 2007 |
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Body Water; Bone Neoplasms; Cell Membrane Permeability; Diffusion Magnetic Resonance Imaging; Feasibility Studies; Goserelin; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Tomography, X-Ray Computed; Tosyl Compounds; Treatment Outcome; Whole Body Imaging | 2007 |
Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Leuprolide; Male; Multivariate Analysis; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Nitriles; Prognosis; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 2008 |
Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
Topics: Aged; Androgen Antagonists; Anemia; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Goserelin; Hemoglobins; Humans; Leuprolide; Linear Models; Male; Neoplasm Metastasis; Nitriles; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds | 2008 |
A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Time Factors; Tosyl Compounds; Treatment Outcome | 2009 |
Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Topics: Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Brachytherapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Iodine Radioisotopes; Leuprolide; Male; Nitriles; Palladium; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy Dosage; Relative Biological Effectiveness; Tosyl Compounds; Treatment Failure | 2009 |
Androgen deprivation therapy regulation of beta1C integrin expression in prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Blotting, Northern; Disease Progression; Gene Expression Regulation, Neoplastic; Goserelin; Humans; Integrin beta1; Male; Middle Aged; Nitriles; Prostatic Neoplasms; RNA, Messenger; Tosyl Compounds; Transcription, Genetic | 2009 |
Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer.
Topics: Adenocarcinoma; Anilides; Antineoplastic Agents, Hormonal; B7-1 Antigen; Cancer Vaccines; Goserelin; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Engineering; Radiography, Abdominal; Radiotherapy; T-Lymphocytes; Tosyl Compounds; Ultrasound, High-Intensity Focused, Transrectal; Vaccines, Synthetic | 2009 |
Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI.
Topics: Aged; Androgen Antagonists; Anilides; Blood Volume; Capillary Permeability; Cell Hypoxia; Goserelin; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Oxygen; Prospective Studies; Prostatic Neoplasms; Regional Blood Flow; Reproducibility of Results; Time Factors; Tosyl Compounds | 2011 |
Management of thrombotic thrombocytopenic purpura in metastatic prostate cancer with only endocrine therapy.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Bone Neoplasms; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Purpura, Thrombotic Thrombocytopenic; Tosyl Compounds | 2010 |
[Impact of neoadjuvant hormonal therapy on the permanent ¹²⁵I-seed brachytherapy for localized high-risk prostate cancer].
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Brachytherapy; Goserelin; Humans; Iodine Radioisotopes; Male; Neoadjuvant Therapy; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2010 |
Depression related to (neo)adjuvant hormonal therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Depression; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Prognosis; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds | 2011 |
Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlormadinone Acetate; Disease-Free Survival; Flutamide; Follow-Up Studies; Goserelin; Humans; Japan; Kaplan-Meier Estimate; Leuprolide; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2011 |
DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study.
Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Contrast Media; Diffusion Magnetic Resonance Imaging; Feasibility Studies; Goserelin; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Nitriles; Organometallic Compounds; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2012 |
Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Topics: Analysis of Variance; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-Free Survival; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Seminal Vesicles; Tosyl Compounds | 2012 |
The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Algorithms; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Administration Schedule; Goserelin; Humans; Kaplan-Meier Estimate; Leuprolide; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Nitriles; Odds Ratio; Predictive Value of Tests; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Tosyl Compounds; Treatment Failure; Treatment Outcome | 2012 |
Effects of androgen deprivation on brain function in prostate cancer patients - a prospective observational cohort analysis.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Brain; Cognition; Cohort Studies; Goserelin; Humans; Magnetic Resonance Imaging; Male; Memory; Middle Aged; Neuropsychological Tests; Nitriles; Prospective Studies; Prostatic Neoplasms; Psychomotor Performance; Quality of Life; Surveys and Questionnaires; Tosyl Compounds; Treatment Outcome | 2012 |
[Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Goserelin; Humans; Lymph Node Excision; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2012 |
[Osteosarcoma of the prostate after radiotherapy].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease Progression; Fatal Outcome; Goserelin; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Transurethral Resection of Prostate | 2012 |
Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Down-Regulation; Gene Expression Profiling; Goserelin; Humans; Hypoxia-Inducible Factor 1; Induction Chemotherapy; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Random Allocation; Receptors, Androgen; Stress, Physiological; Tosyl Compounds; Transcription, Genetic; Up-Regulation | 2013 |
Intensity-modulated radiotherapy combined with endocrine therapy for intermediate and advanced prostate cancer: long-term outcome of Chinese patients.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cystitis; Follow-Up Studies; Goserelin; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Proctitis; Prognosis; Prostatic Neoplasms; Radiation Injuries; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Survival Rate; Tosyl Compounds | 2013 |
Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Goserelin; Humans; Lymphatic Metastasis; Male; Nitriles; Prostate; Prostatic Neoplasms; Taxoids; Tosyl Compounds; Treatment Failure; Treatment Outcome | 2014 |
Subjective and Objective Effects of Androgen Ablation Therapy on Voice.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Cross-Sectional Studies; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Voice Quality | 2015 |
Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Gonadotropin-Releasing Hormone; Goserelin; Humans; Lower Urinary Tract Symptoms; Male; Nitriles; Nocturia; Organ Size; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Severity of Illness Index; Tosyl Compounds | 2018 |
Cutaneous Metastases From Adenocarcinoma of the Prostate.
Topics: Adenocarcinoma; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Fatal Outcome; Goserelin; Humans; Lymphatic Metastasis; Male; Nitriles; Prostatic Neoplasms; Skin Neoplasms; Skin Ulcer; Tosyl Compounds; Transurethral Resection of Prostate | 2018 |
Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Arrhythmias, Cardiac; California; Cardiovascular Diseases; Cohort Studies; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Heart Failure; Humans; Imidazolidines; Leuprolide; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Nitriles; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Risk Factors; Tosyl Compounds | 2017 |
Frontal fibrosing alopecia after antiandrogen hormonal therapy in a male patient.
Topics: Adenocarcinoma; Aged, 80 and over; Alopecia; Anilides; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Fibrosis; Goserelin; Humans; Male; Nitriles; Prostatic Neoplasms; Scalp; Skin; Tosyl Compounds | 2018 |
Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Depression; Depressive Disorder; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Hospitalization; Humans; Imidazolidines; Leuprolide; Male; Mental Health Services; Middle Aged; Nitriles; Oligopeptides; Prostatic Neoplasms; Radiotherapy; Retrospective Studies; Suicide; Tosyl Compounds | 2019 |
Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment.
Topics: Aged, 80 and over; Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antigens, Surface; Brachytherapy; Disease Progression; Gallium Radioisotopes; Gene Expression Regulation, Neoplastic; Glutamate Carboxypeptidase II; Goserelin; Humans; Ligands; Male; Nitriles; Positron-Emission Tomography; Programmed Cell Death 1 Receptor; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Tosyl Compounds | 2019 |
Evaluation of effectiveness of antiandrogen treatments on cavernosal tissues in rats.
Topics: Administration, Oral; Androgen Antagonists; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Collagen; Disease Models, Animal; Erectile Dysfunction; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Muscle, Smooth; Nitriles; Orchiectomy; Penis; Prostatic Neoplasms; Rats; Rats, Wistar; Tosyl Compounds | 2020 |
Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kallikreins; Leuprolide; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Testosterone; Tosyl Compounds | 2020 |
Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Lung Diseases, Interstitial; Male; Prostatic Neoplasms; United States; United States Food and Drug Administration | 2023 |